The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 29, 2017

Filed:

Dec. 27, 2013
Applicant:

Massachusetts Eye & Ear Infirmary, Boston, MA (US);

Inventor:

Benjamin S. Bleier, Weston, MA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/277 (2006.01); A61K 38/13 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61K 31/4164 (2006.01); A61K 31/43 (2006.01); A61K 31/4545 (2006.01); A61K 31/47 (2006.01); A61K 31/4725 (2006.01); A61K 31/473 (2006.01); A61K 31/496 (2006.01); A61K 31/545 (2006.01); A61K 31/55 (2006.01); A61K 31/56 (2006.01); A61K 31/573 (2006.01); A61K 31/58 (2006.01); A61K 31/65 (2006.01); A61K 31/7048 (2006.01); A61L 27/20 (2006.01); A61L 27/54 (2006.01);
U.S. Cl.
CPC ...
A61K 38/13 (2013.01); A61K 9/0043 (2013.01); A61K 31/277 (2013.01); A61K 31/4164 (2013.01); A61K 31/43 (2013.01); A61K 31/4545 (2013.01); A61K 31/47 (2013.01); A61K 31/473 (2013.01); A61K 31/4725 (2013.01); A61K 31/496 (2013.01); A61K 31/545 (2013.01); A61K 31/55 (2013.01); A61K 31/56 (2013.01); A61K 31/573 (2013.01); A61K 31/58 (2013.01); A61K 31/65 (2013.01); A61K 31/7048 (2013.01); A61K 45/06 (2013.01); A61L 27/20 (2013.01); A61L 27/54 (2013.01);
Abstract

Provided herein are, inter alia, methods for treating rhinosinusitis with P-glycoprotein inhibitors. A subject having rhinosinusitis is identified and then treated by administration to the subject an effective amount of a P-gp inhibitor. The subject having rhinosinusitis can be identified by one of skill in the art based on known methods, e.g., based on detection of the presence of symptoms, by endoscopy, or by computed tomography. The efficacy of the treatment can be monitored by methods known in the art, e.g., by monitoring symptoms, by endoscopy or computed tomography. The P-glycoprotein inhibitor can be delivered to the subject's nasal passage and sinuses by an inhalation device, by flushing, by spraying, or by an eluting implant surgically placed in the subject's nasal passage or sinuses. The P-glycoprotein inhibitor can also be administered in combination with a corticosteroid.


Find Patent Forward Citations

Loading…